Interchangeability Designation Still Widely Debated, Prescribers Hesitant About Biosimilars
October 19th 2023The FDA is the only authority that can designate a biosimilar as interchangeable with its reference product, which requires that the product has similar clinical results for the same indication.
Read More
AMCP Session Provides Updates on PBM Reform Efforts Currently Stalled in Congress
October 17th 2023Reform efforts to consider how health care plans may capitalize on disclosures, balancing out-of-pocket spending access, and how pharmacists can help plan members with the increased transparency of pharmacy benefit managers.
Read More
Updates in Federal Legislation Addressing Digital Therapeutics, Access to Care
October 17th 2023Although all legislation is currently on hold in Congress, there are important actions under consideration for pharmacy, including digital therapeutics, access to care, and health care disparities.
Read More
Rebyota Found Safe, Effective in Preventing Recurring Clostridioides Difficile Infection
October 16th 2023Treatment-emergent adverse events associated with Rebyota for Clostridioides difficile infection were more prevalent in those with renal comorbidities than in those without and were moderate in severity as well as related to pre-existing conditions.
Read More